Jones I R, Owens D R, Williams S, Ryder R E, Birtwell A J, Jones M K, Gicheru K, Hayes T M
Department of Medicine, Welsh National School of Medicine, Cardiff, United Kingdom.
Diabetes Care. 1983 Sep-Oct;6(5):501-3. doi: 10.2337/diacare.6.5.501.
Glycosylated hemoglobin (HbA1) is widely used as an index of glycemic control in diabetic patients. However, due to the long survival time of erythrocytes (120 days), it remains elevated for several weeks after improved control. Other plasma proteins are similarly glycosylated, and as glycosylated serum albumin (GSA) has a shorter half-life (20 days), it should detect glycemic changes earlier. Fasting blood glucose (FBG), GSA, and HbA1 were measured weekly in newly diagnosed diabetic patients (N = 12) for 8 wk after beginning treatment. After 4 wk, a similar fall in FBG and GSA levels, i.e., 72% and 58% respectively, was observed. In contrast, HbA1 fell significantly less (P less than 0.01), by only 39% of its initial value. By 8 wk there was no significant difference between the percentage reduction in the three indices of control. Therefore, GSA provides the clinician with earlier objective evidence of the metabolic response to therapeutic intervention and can be regarded as an intermediate index of diabetic control.
糖化血红蛋白（HbA1）被广泛用作糖尿病患者血糖控制的指标。然而，由于红细胞的存活时间较长（120天），在血糖控制改善后，其水平仍会持续升高数周。其他血浆蛋白也会发生类似的糖基化，由于糖化血清白蛋白（GSA）的半衰期较短（20天），它应该能更早地检测到血糖变化。在新诊断的糖尿病患者（N = 12）开始治疗后的8周内，每周测量空腹血糖（FBG）、GSA和HbA1。4周后，观察到FBG和GSA水平出现类似程度的下降，分别为72%和58%。相比之下，HbA1下降幅度明显较小（P < 0.01），仅为其初始值的39%。到8周时，这三个控制指标的下降百分比之间没有显著差异。因此，GSA为临床医生提供了治疗干预后代谢反应的更早客观证据，可被视为糖尿病控制的一个中间指标。
